Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxoltinib for Lower-Risk Myelofibrosis (Single-Arm Phase 2 Study)
ChiCTR2200064250Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in myelofibrosis (MF), primary myelofibrosis (PMF) and post-polycythemia vera myelofibrosis (PPV-MF), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Clinical efficacy, Spleen size and 2 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on ChiCTR2200064250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064250.